Skyrizi® is the commercial brand name of Risankizumab Injection, a fully human monoclonal antibody targeting IL‑23p19 developed by AbbVie. It selectively binds interleukin‑23 and blocks downstream inflammatory pathways to suppress excessive immune inflammation.
Main Indications
Treatment of moderately to severely active Crohn’s disease in adult patients with inadequate response, loss of response or intolerance to conventional therapy or biologic agents;
Treatment of moderate to severe plaque psoriasis suitable for systemic therapy in adult patients;
Treatment of active psoriatic arthritis in adult patients.
Clinical Research
Global multicenter phase III pivotal trials confirmed that risankizumab achieves high rates of clinical remission and mucosal healing in Crohn’s disease, and enables sustained skin lesion clearance in plaque psoriasis;
Registration trials conducted in Chinese patients demonstrated consistent therapeutic efficacy and comparable safety profiles with global trial cohorts;
Long-term extension studies verified stable long-term disease control and a predictable safety profile during continuous maintenance treatment.
Common Side Effects
Severe but important risks: Serious infections including tuberculosis and invasive fungal infections, severe hypersensitivity reactions, hepatic adverse events;
Common mild adverse reactions: Upper respiratory tract infection, headache, fatigue, diarrhoea, abdominal discomfort and injection site reactions.
Approval Status in China
Original drug Skyrizi® (Risankizumab Injection) was officially approved for marketing in China, with the specification of 600mg/10mL per vial. It is a prescription biologic agent.
Buy Skyrizi (Risankizumab Injection) online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
